Business Context and Reporting Period
Company: Merit Medical Systems, Inc. (MMSI)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2026
Segment Reporting: Effective Q1 2026, the company reports as a single operating segment with two product categories: Foundational and Therapeutic. Martha G. Aronson serves as the Chief Executive Officer and Chief Operating Decision Maker.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Sales | $381.9 million | $355.4 million |
| Gross Profit | $184.8 million | $172.0 million |
| Gross Margin | 48.4% | 48.4% |
| Operating Income | $44.2 million | $41.0 million |
| Net Income | $41.0 million | $30.1 million |
| Diluted EPS | $0.68 | $0.49 |
| Operating Cash Flow | $40.7 million | $40.6 million |
| Cash & Equivalents (End of Period) | $488.1 million | $395.5 million |
| Long-Term Debt | $735.2 million | $734.0 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 7.5% year-over-year, driven by 6.3% growth in Foundational products and 9.9% growth in Therapeutic products. International sales grew 9.6% compared to 6.1% domestically.
- Profitability: Net income increased 36% to $41.0 million. This was significantly aided by a $12.5 million pre-tax gain from the divestiture of the DualCap product line to Health Line.
- Operating Expenses: SG&A expenses rose 10.0% to $118.2 million, primarily due to increased labor costs, commissions, and headcount additions related to recent acquisitions (Biolife, C2). R&D expenses remained relatively flat at $22.6 million.
- Tax Rate: The effective tax rate increased to 23.4% from 20.6%, attributed to decreased benefits from discrete items and the tax impacts of recent M&A activity.
- Acquisitions & Divestitures:
- Divestiture: Sold DualCap product line for $28 million (received $25.5 million cash at closing).
- Acquisitions: Completed C2 CryoBalloon acquisition (Nov 2025) and Biolife Merger (May 2025). Subsequent event: Acquired View Point Medical on April 1, 2026, for approx. $140 million.
Guidance, Outlook, and Risks
- Capital Expenditures: Management anticipates spending approximately $80 million to $100 million on property and equipment in 2026.
- Liquidity: The company maintains strong liquidity with $490.2 million in cash and restricted cash, plus approximately $697 million in available borrowing capacity under its credit agreement.
- Tariff Uncertainty: Following a U.S. Supreme Court ruling on IEEPA tariffs, the company is evaluating potential refunds for raw materials but has not recorded a benefit due to uncertainty regarding timing and amounts.
- Geopolitical Risks: Ongoing conflict between the U.S., Israel, and Iran poses risks to global energy supplies, input costs (resins), and supply chain stability.
- Convertible Notes: $747.5 million in convertible notes outstanding, maturing in 2029. No early conversion conditions were met as of March 31, 2026.
Investor Verification Checklist
- Divestiture Gain: Verify the sustainability of earnings given the $12.5 million one-time gain from the DualCap sale.
- Inventory Build: Review the $22.7 million cash outflow for inventory, driven by strategic stockpiling and safety stock increases.
- View Point Integration: Monitor the integration progress and purchase price allocation for the $140 million View Point Medical acquisition closed in April 2026.
- Tariff Recovery: Track the status of potential tariff refunds following the Supreme Court ruling.
- Debt Covenants: Confirm continued compliance with leverage ratios under the Amended Fourth A&R Credit Agreement.